Many patients are being treated with costly new radiotherapy treatments on the basis of hype rather than evidence that they stand to benefit. For others, lack of evidence is delaying access to new treatments that [more]
When we talk about advances in cancer care patient advocacy groups tend to focus on the development of new drugs, immunotherapy being the latest flavour. This is encouraged by the pharma industry, keen to gain [more]
Could the new generation of antibodydrug conjugates herald a move away from conventional untargeted chemotherapy? Much will depend on how far and in whom their added benefit can justify the high cost of [more]